To review the mechanisms through which adipose-derived stem cell exosomes (ADSC-Exos) facilitate diabetic wound healing and to explore their clinical applications, highlighting the significance of these findings in the context of existing treatment strategies.
Key Findings:
ADSC-Exos have significant clinical potential as a cell-free therapy for diabetic foot ulcers.
They facilitate wound healing by delivering bioactive molecules that activate healing mechanisms.
ADSC-Exos can be produced from easily accessible adipose tissue, enhancing their clinical scalability.
Current therapies have limitations that ADSC-Exos may address.
Interpretation:
ADSC-Exos represent a promising therapeutic approach for diabetic foot ulcers, but their clinical application is hindered by variability in exosome cargo and a lack of robust human clinical trials. Future research should focus on standardization and efficacy in clinical settings.
Limitations:
Heterogeneity and cargo variability of ADSC-Exos complicate standardization and may lead to inconsistent clinical outcomes.
Overreliance on preclinical models limits the applicability of findings to human clinical settings, necessitating more human trials.
Conclusion:
The review provides a roadmap for developing effective, cell-free therapies for diabetic foot ulcers by optimizing exosome production and delivery methods, while addressing the identified limitations to enhance clinical application.
